Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

The move will also “significantly free up clinical time” by reducing the need for hospital appointments, officials said. | ITV National News ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. Blair, best known for her roles in turn ...

There are many treatment options for multiple sclerosis (MS). For medications, they may be injected, infused, or swallowed. Multiple sclerosis (MS) is an autoimmune disorder in which the body’s ...

The second deal is with German pharma company Merck for its multiple sclerosis drug Mavenclad (cladribine), and involves a new outcomes-based pricing agreement. Simon Stevens hailed the Merck ...